Extracorporeal carbon dioxide removal in acute hypoxaemic respiratory failure: a systematic review, Bayesian meta-analysis and trial sequential analysis.

Millar, J. E., Boyle, A. J., Drake, T. M., Adams, C. E., Glass, A. W., Blackwood, B., McNamee, J. J. and McAuley, D. F. (2022) Extracorporeal carbon dioxide removal in acute hypoxaemic respiratory failure: a systematic review, Bayesian meta-analysis and trial sequential analysis. European Respiratory Review, 31, 220030. (doi: 10.1183/16000617.0030-2022) (PMID:36384701) (PMCID:PMC9724795)

Abstract

Purpose: To assess the safety and efficacy of extracorporeal carbon dioxide removal (ECCO2R) versus standard care in patients with acute hypoxaemic respiratory failure (AHRF). Methods: MEDLINE, Embase and clinical trial registries were searched from 1994 to 31 December 2021. We included randomised controlled trials (RCTs) and observational studies. Pairs of reviewers independently extracted data and assessed the risk of bias. The primary outcome was mortality. Secondary outcomes included ventilator-free days, length of stay, safety and adverse events and physiological changes. As a primary analysis, we performed a meta-analysis of mortality until day 30 using a Bayesian random effects model. We then performed a trial sequential analysis of RCTs. Results: 21 studies met inclusion criteria: three RCTs, enrolling 531 patients, and 18 observational studies. In a pooled analysis of RCTs, the posterior probability of increased mortality with the use of ECCO2R was 73% (relative risk 1.19, 95% credible interval 0.70–2.29). There was substantial heterogeneity in the reporting of safety and adverse events. However, the incidence of extra and intracranial haemorrhage was higher (relative risk 3.00, 95% credible interval 0.41–20.51) among those randomised to ECCO2R. Current trials have accumulated 80.8% of the diversity-adjusted required information size and the lack of effect reaches futility for a 10% absolute risk reduction in mortality. Conclusions: The use of ECCO2R in patients with AHRF is not associated with improvements in clinical outcomes. Furthermore, it is likely that further trials of ECCO2R aiming to achieve an absolute risk reduction in mortality of ≥10% are futile.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Glass, Dr Adam
• Authors: Millar, J. E., Boyle, A. J., Drake, T. M., Adams, C. E., Glass, A. W., Blackwood, B., McNamee, J. J., and McAuley, D. F.
• College/School: College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
• Journal Name: European Respiratory Review
• ISSN: 0905-9180
• ISSN (Online): 1600-0617
• Published Online: 15 November 2022
• Copyright Holders: Copyright © 2022 The Authors
• First Published: First published in European Respiratory Review 31:220030
• Publisher Policy: Reproduced under a Creative Commons License